ICML 2019
CAR-T: from therapy development to patient response

The emerging Chimeric Antigen Receptor (CAR) T-cell therapy axicabtagene ciloleucel serves as a potential treatment for relapsed/refractory diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after ≥ two lines of systemic therapy.

Follow the journey of CAR T-cell therapy from its initial development, manufacturing process, and product optimization, to key factors which influence patient outcomes.

VJHemOnc talked to leading experts from the Kite Satellite Symposia ‘CAR T: from bed to bench and back again’ and ‘CAR T: a closer look behind the cells’, hosted during the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland, June 2019. These sessions included discussion on licensed products, and were organized and fully funded by Kite, a Gilead Company.

CAR-T: from bed to bench and back again

Featured speakers:
John Rossi, Kite, a Gilead Company
Claire Roddie, London, UK
Christian Chabannon, Marseille, France
Chris Shen, Kite, a Gilead Company
Louis van de Wiel, Kite, a Gilead Company

Satellite Symposium I
CAR-T: a closer look at the science behind the cells

Featured speakers:
Max Topp, Wurzburg, Germany
Chiara Bonini, Milan, Italy

Satellite Symposium II

Axicabtagene ciloleucel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. Axicabtagene ciloleucel must be administered at a qualified clinical setting.

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. For Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971. Adverse events should also be reported to Gilead at safety_FC@gilead.com or +44 (0) 1223 897500.

YESCARTA® (axicabtagene ciloleucel), Kite and the Kite logo are registered trademarks of Kite Pharma Inc © 2019 Kite Pharma, Inc.